Biolase Revenue 2006-2020 | BIOL

Biolase revenue from 2006 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Biolase Annual Revenue
(Millions of US $)
2019 $38
2018 $46
2017 $47
2016 $52
2015 $48
2014 $48
2013 $56
2012 $57
2011 $49
2010 $26
2009 $43
2008 $65
2007 $67
2006 $70
2005 $62
Biolase Quarterly Revenue
(Millions of US $)
2020-03-31 $5
2019-12-31 $10
2019-09-30 $9
2019-06-30 $9
2019-03-31 $10
2018-12-31 $13
2018-09-30 $11
2018-06-30 $12
2018-03-31 $10
2017-12-31 $13
2017-09-30 $11
2017-06-30 $13
2017-03-31 $11
2016-12-31 $14
2016-09-30 $13
2016-06-30 $14
2016-03-31 $11
2015-12-31 $15
2015-09-30 $11
2015-06-30 $12
2015-03-31 $11
2014-12-31 $13
2014-09-30 $13
2014-06-30 $10
2014-03-31 $12
2013-12-31 $15
2013-09-30 $12
2013-06-30 $14
2013-03-31 $15
2012-12-31 $19
2012-09-30 $14
2012-06-30 $12
2012-03-31 $12
2011-12-31 $13
2011-09-30 $13
2011-06-30 $12
2011-03-31 $11
2010-12-31 $10
2010-09-30 $6
2010-06-30 $6
2010-03-31 $4
2009-12-31 $10
2009-09-30 $12
2009-06-30 $14
2009-03-31 $7
2008-12-31 $12
2008-09-30 $15
2008-06-30 $19
2008-03-31 $19
2007-12-31 $21
2007-09-30 $13
2007-06-30 $18
2007-03-31 $15
2006-12-31 $20
2006-09-30 $17
2006-06-30 $16
2006-03-31 $17
2005-12-31 $19
2005-09-30 $12
2005-06-30 $15
2005-03-31 $17
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $0.013B $0.038B
Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
Stock Name Country Market Cap PE Ratio
Becton Dickinson (BDX) United States $66.961B 21.31
McKesson (MCK) United States $28.073B 10.59
AmerisourceBergen (ABC) United States $19.392B 12.66
Align Technology (ALGN) United States $19.346B 10.55
Laboratory Of America Holdings (LH) United States $17.041B 15.85
Cooper (COO) United States $16.905B 26.07
Cardinal Health (CAH) United States $15.969B 9.91
West Pharmaceutical Services (WST) United States $15.901B 61.55
Straumann Holding AG (SAUHF) Switzerland $12.813B 0.00
DENTSPLY SIRONA (XRAY) United States $10.192B 19.46
Henry Schein (HSIC) United States $8.668B 16.64
SmileDirectClub (SDC) United States $3.007B 0.00
Merit Medical Systems (MMSI) United States $2.492B 30.40
CONMED (CNMD) United States $2.094B 28.34
Patterson (PDCO) United States $1.886B 13.13
STAAR Surgical (STAA) United States $1.750B 92.38
Atrion (ATRI) United States $1.179B 33.01
Antares Pharma (ATRS) United States $0.475B 143.50
Lifevantage (LFVN) United States $0.219B 18.45
Invacare (IVC) United States $0.212B 0.00
Retractable Technologies (RVP) United States $0.178B 60.44
Milestone Scientific (MLSS) United States $0.102B 0.00
Pro-Dex (PDEX) United States $0.076B 18.07
Endologix (ELGX) United States $0.014B 0.00